STING1 and neoplasm: STING-low: D4M3A bilateral model — T-VEC monotherapy eradicated both injected and non-injected lesions, reversing PD-1 resistance STING-high: YUMM1.7 — limited T-VEC replication; no added benefit with PD-1 blockade STING-high + JAKi: T-VEC + Ruxolitinib led to 80% tumor shrinkage at injection sites and 40% abscopal response